Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 236

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 236
---
 • |     | overall performance of the equity markets and other factors that may be unrelated to New Semnur’s operating performance or the operating performance of its competitors, including changes in market valuations of similar companies; |

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by New Semnur or its competitors; |

| • |     | changes in financial estimates by New Semnur or by any securities analysts who might cover its stock; |

| • |     | fluctuation of the market values of any of New Semnur’s potential strategic investments; |

| • |     | issuances of debt or equity securities; |

| • |     | compliance with New Semnur’s contractual obligations; |

| • |     | sales of New Semnur Common Stock by New Semnur or its stockholders in the future; |

| • |     | trading volume of New Semnur Common Stock; |

| • |     | ineffectiveness of New Semnur’s internal controls; |

| • |     | publication of research reports about New Semnur or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; |

| • |     | New Semnur’s relationship with Scilex; |

| • |     | general political and economic conditions, including the wars in Ukraine and Israel; |

| • |     | effects of natural or man-made catastrophic events; |

| • |     | effects of public health crises, pandemics and epidemics; and |

| • |     | other events or factors, many of which are beyond New Semnur’s control, such as the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions. |

Further, the global equity markets in general have recently experienced extreme price and volume fluctuations, including as a result of the COVID-19 pandemic,economic uncertainty and increased interest rates, inflation, the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions that may be unrelated to New Semnur’s operating performance. Continued market fluctuations could result in extreme volatility in the price of New Semnur Common Stock, which could cause a decline in the value of its common stock. Price volatility of New Semnur Common Stock might worsen if the trading volume of its common stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies’